Curis | CRIS - Sales Revenues


Curis reported $2.55M in Sales Revenues for its fiscal quarter ending in June of 2024.





Sales Change Date
Alaunos Therapeutics USD 2K 2K Mar/2025
Amgen USD 9.9B 340M Dec/2025
AstraZeneca USD 15.5B 313M Dec/2025
Bayer EUR 11.44B 1.78B Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
CSL USD 8.33B 4.79B Dec/2025
Curis USD 2.55M 460K Jun/2024
Eli Lilly USD 19.3B 1.7B Dec/2025
Exelixis USD 598.66M 860K Dec/2025
Gilead Sciences USD 7.93B 130M Dec/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
Incyte USD 1.51B 140M Dec/2025
Merck USD 16.4B 880M Dec/2025
Novartis USD 13.86B 50M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Sanofi EUR 11.3B 1.13B Dec/2025
Takeda JPY 1.19T 80B Dec/2025
TG Therapeutics USD 192.57M 30.87M Dec/2025
Verastem USD 0 10M Sep/2024
Xoma USD 25K 5M Sep/2024